日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide

新型NPY2R激动剂BI 1820237与GCGR/GLP-1R双重激动剂苏沃度肽联合使用时,可产生协同抗肥胖疗效。

Augustin, Robert; Oldenburger, Anouk; Baader-Pagler, Tamara; Zimmermann, Tina; Borghardt, Jens; Hecksher-Sørensen, Jacob; Baljuls, Angela; Reindl, Wolfgang; Krawczyk, Bartlomiej; Martel, Eric; Brennauer, Albert; Peters, Stefan; Grube, Achim; Rudkjaer, Lise Biehl; Haebel, Peter

GPR101 loss promotes insulin resistance and diet-induced obesity risk.

GPR101 缺失会促进胰岛素抵抗和饮食诱导的肥胖风险

Garrett Lillian, Irmler Martin, Baljuls Angela, Rathkolb Birgit, Dragano Nathalia, Gerlini Raffaele, Sanz-Moreno Adrián, Aguilar-Pimentel Antonio, Becker Lore, Kraiger Markus, Reithmeir Rosa, Beckers Johannes, Calzada-Wack Julia, Wurst Wolfgang, Fuchs Helmut, Gailus-Durner Valerie, Zimmermann Tina, Hölter Sabine M, de Angelis Martin Hrabě